• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生理水平的 PTEN-PI3K-AKT 轴活性是维持伯基特淋巴瘤所必需的。

Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.

机构信息

Institute of Physiological Chemistry, University of Ulm, Ulm, Germany.

Institute of Pathology, University of Ulm, Ulm, Germany.

出版信息

Leukemia. 2020 Mar;34(3):857-871. doi: 10.1038/s41375-019-0628-0. Epub 2019 Nov 12.

DOI:10.1038/s41375-019-0628-0
PMID:31719683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7214272/
Abstract

In addition to oncogenic MYC translocations, Burkitt lymphoma (BL) depends on the germinal centre (GC) dark zone (DZ) B cell survival and proliferation programme, which is characterized by relatively low PI3K-AKT activity. Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. Here we show that the PI3K-AKT activity in primary BLs and BL cell lines does not exceed that of human non-neoplastic tonsillar GC DZ B cells. BLs were not sensitive to AKT1 knockdown, which induced massive cell death in pAKT DLBCL cell lines. Likewise, BL cell lines show low sensitivity to pan-AKT inhibitors. Moreover, hyper-activation of the PI3K-AKT pathway by overexpression of a constitutively active version of AKT (myrAKT) or knockdown of PTEN repressed the growth of BL cell lines. This was associated with increased AKT phosphorylation, NF-κB activation, and downregulation of DZ genes including the proto-oncogene MYB and the DZ marker CXCR4. In contrast to GCB-DLBCL, PTEN overexpression was tolerated by BL cell lines. We conclude that the molecular mechanisms instrumental to guarantee the survival of normal DZ B cells, including the tight regulation of the PTEN-PI3K-AKT axis, also operate in the survival/proliferation of BL.

摘要

除致癌性 MYC 易位外,伯基特淋巴瘤(BL)还依赖生发中心(GC)暗区(DZ)B 细胞的存活和增殖程序,其特征是 PI3K-AKT 活性相对较低。矛盾的是,PI3K-AKT 的激活促进了小鼠中 MYC 驱动的淋巴瘤发生,并且有人提出 PI3K-AKT 的激活对于 BL 是必需的。在这里,我们表明,原发性 BL 和 BL 细胞系中的 PI3K-AKT 活性不超过人类非肿瘤性扁桃体 GC DZ B 细胞。BL 对 AKT1 敲低不敏感,AKT1 敲低会诱导 pAKT DLBCL 细胞系中大量细胞死亡。同样,BL 细胞系对 pan-AKT 抑制剂的敏感性也较低。此外,通过过表达 AKT(myrAKT)的组成性激活形式或敲低 PTEN 来过度激活 PI3K-AKT 通路会抑制 BL 细胞系的生长。这与 AKT 磷酸化、NF-κB 激活以及 DZ 基因的下调有关,包括原癌基因 MYB 和 DZ 标记物 CXCR4。与 GCB-DLBCL 相反,PTEN 的过表达可被 BL 细胞系耐受。我们的结论是,保证正常 DZ B 细胞存活的分子机制,包括 PTEN-PI3K-AKT 轴的严格调节,也在 BL 的存活/增殖中起作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/6da63e59262e/41375_2019_628_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/c4e12318e633/41375_2019_628_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/6e1862fc48ca/41375_2019_628_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/57ff3f5abd39/41375_2019_628_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/5c8872e5422d/41375_2019_628_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/0772b55057e1/41375_2019_628_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/842ce6434942/41375_2019_628_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/6da63e59262e/41375_2019_628_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/c4e12318e633/41375_2019_628_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/6e1862fc48ca/41375_2019_628_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/57ff3f5abd39/41375_2019_628_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/5c8872e5422d/41375_2019_628_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/0772b55057e1/41375_2019_628_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/842ce6434942/41375_2019_628_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/103e/7214272/6da63e59262e/41375_2019_628_Fig7_HTML.jpg

相似文献

1
Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.生理水平的 PTEN-PI3K-AKT 轴活性是维持伯基特淋巴瘤所必需的。
Leukemia. 2020 Mar;34(3):857-871. doi: 10.1038/s41375-019-0628-0. Epub 2019 Nov 12.
2
SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma.SPAG6 通过 PTEN/PI3K/AKT 通路促进伯基特淋巴瘤细胞增殖并抑制细胞凋亡。
Oncol Rep. 2020 Nov;44(5):2021-2030. doi: 10.3892/or.2020.7776. Epub 2020 Sep 22.
3
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.抑制热休克蛋白 90 抑制 PI3K/AKT/mTOR 信号通路并具有伯基特淋巴瘤的抗肿瘤活性。
Mol Cancer Ther. 2017 Sep;16(9):1779-1790. doi: 10.1158/1535-7163.MCT-16-0848. Epub 2017 Jun 15.
4
IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.IGF-1 通过激活胰腺癌细胞中的 IGF-1/PI3K/Akt 信号通路来介导 PTEN 抑制,增强细胞侵袭和增殖。
J Surg Res. 2010 May 1;160(1):90-101. doi: 10.1016/j.jss.2008.08.016. Epub 2008 Sep 13.
5
Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.槲皮素同时降低c-Myc表达和PI3K/AKT/mTOR信号传导,对伯基特淋巴瘤产生强烈的细胞毒性作用。
Int J Biochem Cell Biol. 2016 Oct;79:393-400. doi: 10.1016/j.biocel.2016.09.006. Epub 2016 Sep 9.
6
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.PTEN 缺失定义了弥漫性大 B 细胞淋巴瘤中依赖 PI3K/AKT 通路的生发中心亚型。
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5. doi: 10.1073/pnas.1305656110. Epub 2013 Jul 9.
7
Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.弥漫性大B细胞淋巴瘤中AKT磷酸化、PTEN缺失的评估及其与利妥昔单抗耐药性的相关性。
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14875-84. eCollection 2015.
8
Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.肺癌中PTEN/PI3K/AKT途径内发生的多种致癌改变所诱导的特定基因表达特征。
PLoS One. 2017 Jun 29;12(6):e0178865. doi: 10.1371/journal.pone.0178865. eCollection 2017.
9
Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.紫草素通过抑制 C-MYC 和 PI3K/AKT/mTOR 通路发挥抗伯基特淋巴瘤活性,并与阿霉素具有协同作用。
Sci Rep. 2018 Feb 20;8(1):3317. doi: 10.1038/s41598-018-21570-z.
10
l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.L-天冬酰胺酶通过 PI3K/Akt/mTOR 通路与依托泊苷协同作用于 EBV 阳性伯基特淋巴瘤。
J Biochem Mol Toxicol. 2022 Aug;36(8):e23117. doi: 10.1002/jbt.23117. Epub 2022 Jun 27.

引用本文的文献

1
Common origins of autoimmune diseases and lymphoid malignancies.自身免疫性疾病和淋巴系统恶性肿瘤的共同起源。
Trends Immunol. 2025 Aug 14. doi: 10.1016/j.it.2025.07.010.
2
CXCR Family and Hematologic Malignancies in the Bone Marrow Microenvironment.CXCR家族与骨髓微环境中的血液系统恶性肿瘤
Biomolecules. 2025 May 13;15(5):716. doi: 10.3390/biom15050716.
3
An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway.一篇最新综述总结了黄酮类化合物通过靶向核因子-κB通路的抗癌潜力。

本文引用的文献

1
Sporadic and endemic Burkitt lymphoma have frequent mutations but distinct hotspots in the AKT recognition motif.散发性和地方性 Burkitt 淋巴瘤有频繁的突变,但在 AKT 识别基序中有不同的热点。
Blood Adv. 2019 Jul 23;3(14):2118-2127. doi: 10.1182/bloodadvances.2018029546.
2
Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.PTEN、NF-κB、WWP2、p53和c-Myc在B细胞淋巴瘤不同亚型及反应性滤泡增生中的表达失调。
Am J Transl Res. 2019 Feb 15;11(2):1092-1101. eCollection 2019.
3
S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.
Front Pharmacol. 2025 Jan 6;15:1513422. doi: 10.3389/fphar.2024.1513422. eCollection 2024.
4
Unraveling the complex role of neutrophils in lymphoma: From pathogenesis to therapeutic approaches (Review).解析中性粒细胞在淋巴瘤中的复杂作用:从发病机制到治疗方法(综述)
Mol Clin Oncol. 2024 Sep 12;21(5):85. doi: 10.3892/mco.2024.2783. eCollection 2024 Nov.
5
Mutant FOXO1 controls an oncogenic network via enhancer accessibility.突变 FOXO1 通过增强子可及性控制致癌网络。
Cell Genom. 2024 Apr 10;4(4):100537. doi: 10.1016/j.xgen.2024.100537.
6
Dependency of B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma Cell Lines on MEN1 Extends beyond MEN1-KMT2A Interaction.依赖 MEN1 的 B 细胞急性淋巴细胞白血病和多发性骨髓瘤细胞系超出了 MEN1-KMT2A 相互作用的范围。
Int J Mol Sci. 2023 Nov 17;24(22):16472. doi: 10.3390/ijms242216472.
7
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism.SH2 结构域内含肌醇 5-磷酸酶通过促进能量代谢支持伯基特淋巴瘤细胞的存活。
Haematologica. 2024 May 1;109(5):1445-1459. doi: 10.3324/haematol.2023.283663.
8
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.TAS0612 通过靶向作用于 PDPK1 的下游效应因子 RSK、AKT 和 S6K 来治疗 B 细胞淋巴瘤。
Cancer Sci. 2023 Dec;114(12):4691-4705. doi: 10.1111/cas.15995. Epub 2023 Oct 15.
9
Extracellular shuttling miR-21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog.细胞外穿梭 miR-21 有助于肿瘤微环境中的食管癌和人脐静脉内皮细胞的通讯,并通过靶向磷酸酶和张力蛋白同源物促进肿瘤血管生成。
Thorac Cancer. 2023 Nov;14(31):3119-3132. doi: 10.1111/1759-7714.15103. Epub 2023 Sep 19.
10
RNA-seq analysis reveals candidate genes associated with proliferation, invasion, and migration in BCL11A knockdown B-NHL cell lines.RNA-seq 分析揭示了与 BCL11A 敲低 B-NHL 细胞系增殖、侵袭和迁移相关的候选基因。
Ann Hematol. 2023 Jul;102(7):1845-1856. doi: 10.1007/s00277-023-05247-w. Epub 2023 May 6.
S-香叶基香叶基-L-谷胱甘肽是人 B 细胞限制受体 P2RY8 的配体。
Nature. 2019 Mar;567(7747):244-248. doi: 10.1038/s41586-019-1003-z. Epub 2019 Mar 6.
4
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.针对伯基特淋巴瘤中PI3K/Akt/mTOR通路的临床前活性
Oncotarget. 2018 Apr 24;9(31):21820-21830. doi: 10.18632/oncotarget.25072.
5
Autoimmunity checkpoints as therapeutic targets in B cell malignancies.自身免疫检查点作为 B 细胞恶性肿瘤的治疗靶点。
Nat Rev Cancer. 2018 Feb;18(2):103-116. doi: 10.1038/nrc.2017.111. Epub 2018 Jan 5.
6
Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.具有伯基特淋巴瘤特征的成人高级别B细胞淋巴瘤:基因组特征及潜在治疗靶点
Blood. 2017 Oct 19;130(16):1819-1831. doi: 10.1182/blood-2017-02-767335. Epub 2017 Aug 11.
7
Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤中的强直性B细胞受体信号传导
Blood. 2017 Aug 24;130(8):995-1006. doi: 10.1182/blood-2016-10-747303. Epub 2017 Jun 23.
8
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.PI3K 和 AKT 抑制剂在 DLBCL 亚型中的敏感性是由不同的分子机制介导的。
Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.
9
Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.小细胞和侵袭性B细胞非霍奇金淋巴瘤中zeste同源物2(EZH2)蛋白的差异表达以及侵袭性B细胞淋巴瘤中p-ERK1/2和MYC对EZH2表达的差异调节。
Mod Pathol. 2016 Sep;29(9):1050-7. doi: 10.1038/modpathol.2016.114. Epub 2016 Jun 10.
10
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类(2016年修订版)》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.